知镜 Cognispect · 医学文献与研究工作台

Efficacy and safety of dupilumab in moderate-to-severe atopic dermatitis with stage 3-5 chronic kidney disease: a retrospective real-world study.

Wei J, Huang Y.
Frontiers in medicine · 2026-09-14 · PMID 42806983

文献摘要

Aims To evaluate dupilumab efficacy and safety in stage 3-5 chronic kidney disease (CKD) patients with moderate-to-severe atopic dermatitis (AD). Methods This retrospective study included 29 such patients receiving dupilumab who completed 12 and 24 weeks of follow-up. Assessments included Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale ( N RS), Sleep NRS, Dermatology Life Quality Index (DLQI), and Clinical Frailty Scale (CFS), eosinophils, interleukin-10 (IL-10), regulatory T cell (Treg) proportions, and renal function [estimated glomerular filtration rate (eGFR), serum creatinine, and urine protein-to-creatinine ratio (UPCR)]. Adverse events were recorded. Results At week 12, mean EASI score decreased from 34.94 ± 7.96 at baseline to 19.31 ± 6.09 (44.7% reduction), with 76.0% of patients achieving EASI-50. Pruritus NRS decreased from 7.72 ± 1.75 to 3.72 ± 1.75 (51.8% reduction), and 88.0% achieved a ≥ 4-point improvement. DLQI improved by 52.1%, and 100% of patients achieved a ≥ 4-point improvement. CFS score decreased by 17.5%. Eosinophil counts decreased by 25.0%, while IL-10 and Treg proportions increased by 49.9% and 50.8%, respectively. At week 24, EASI-50, EASI-75, and EASI-90 response rates were 100%, 76.9%, and 7.7%, respectively; 100% of patients achieved ≥4-point improvements in both pruritus NRS and DLQI. IL-10 and Treg continued to rise, and CFS score was significantly reduced from baseline ( P = 0.001). Renal function parameters remained stable throughout the 24-week follow-up: mean eGFR showed a minimal decline from 37.93 ± 14.88 to 36.39 ± 14.77 mL/min/1.73 m 2 at week 24 ( P = 0.073), serum creatinine and UPCR also showed no significant changes ( P = 0.130 and P = 0.069, respectively). Only two mild-to-moderate adverse events (injection-site reaction and conjunctivitis) occurred, both resolved with symptomatic management. No treatment discontinuation, death, or worsening of renal function was reported. Conclusion Dupilumab effectively improves skin lesions, pruritus, sleep, quality of life, and frailty, while showing changes consistent with regulatory immune modulation in patients with stage 3-5 CKD and moderate-to-severe AD, with a favorable safety profile. Renal impairment alone should not be considered an absolute contraindication, although patients with advanced CKD require careful monitoring.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。